Navigation Links
New Lipitor Diabetes Lawsuit Alleges Statin Drug Caused Woman to Develop Type 2 Diabetes, Learns Wright & Schulte LLC
Date:12/4/2013

Columbus, OH (PRWEB) December 04, 2013

Wright & Schulte LLC has learned that a woman from West Virginia recently filed a new Lipitor diabetes lawsuit alleging that the use of the cholesterol-lowering statin caused her to develop new-onset Type 2 diabetes. According to a November 6th report from the West Virginia Record, the Plaintiff developed diabetes after she had been taking Lipitor for about four years. The diabetes ultimately caused her to suffer vision loss in both eyes, forcing her to undergo cataract surgery. Among other things, the Lipitor diabetes lawsuit alleges that Pfizer, Inc. failed to provide proper warnings regarding the risks associated with the medication. Wright & Schulte will continue to monitor Lipitor proceedings and speaking with people who may have been effected by Lipitor side-effects such as Type 2 Diabetes.
[wvrecord.com/news/263884-martinsburg-woman-files-
lipitor-suit-against-pfizer]

Wright & Schulte LLC has learned through the U.S. Food & Drug Administration (FDA), that Lipitor is prescribed to people who have heart disease, or risk factors for heart disease, to lower their chances for heart attack, stroke, certain types of heart surgery, and chest pain. According to a recent report from Forbes, Lipitor ranked as the best-selling drug of all time until it lost patent protection in 2011.
[fda.gov/newsevents/newsroom/pressannouncements
/ucm281817.htm, FDA, November 2011]
[forbes.com/sites/johnlamattina/2013/10/16/why-is-it
-so-hard-to-predict-sales-of-new-drugs/, Forbes, October 16, 2013]

FDA Warning on Lipitor Side-Effects
The law firm also points out, the FDA released a drug safety communication in February 2012, warning that Lipitor could be associated with an increased risk of new-onset diabetes. The agency also ordered Pfizer, Inc. to change the Lipitor label to reflect this risk.
[fda.gov/drugs/drugsafety/ucm293101.htm, FDA, February 2012]

Wright & Schulte LLC further points out the lawsuit, in the U.S. Judicial Panel on Multidistrict Litigation (JPML), is currently considering a motion to consolidate all Lipitor diabetes lawsuits involving diabetes allegations in a single federal court for pretrial proceeding. According to the October 10th motion, dozens of product liability claims are currently pending in courts around the country, all of which share common allegations of fact involving Pfizer’s testing, manufacturing and marketing of Lipitor, and the warnings it provided concerning the drug’s potential link to Type 2 diabetes. The motion also acknowledges that this is the second time that plaintiffs have sought the consolidation of Lipitor diabetes lawsuits, as an earlier petition was rejected by the JPML in August. The new motion asserts that an increase in filings since then warrants reconsideration by the Panel. (In re Lipitor (Atorvastatin) Litigation, MDL No. 2502 (JPML))

According to Wright & Schulte LLC, the consolidation of federally-filed Lipitor diabetes lawsuits would preserve the resources of the court, witnesses and parties by allowing the claims to undergo coordinated pretrial proceedings, including discovery. Such proceedings also avoid inconsistent rulings and duplicative discovery in cases where a large number of lawsuits share common allegations of fact.

Wright & Schulte LLC is now offering free legal consultations to individuals who may have developed Type 2 diabetes due to Lipitor. To learn more about filing a Lipitor diabetes lawsuit from an attorney at Wright & Schulte LLC, please visit yourlegalhelp.com.

About Wright & Schulte LLC And Filing A Lipitor Type 2 Diabetes Lawsuit
Wright & Schulte LLC, an experienced personal injury firm, is dedicated to the belief that America’s legal system should work for the people. Every day, the attorneys of Wright & Schulte LLC stand up for the rights of people who have been injured or wronged and fight tirelessly to ensure that even the world’s most powerful corporations take responsibility for their actions. If you’re looking for a law firm that will guarantee the aggressive and personal representation you deserve, please do not hesitate to contact Wright & Schulte LLC today. Free Lipitor diabetes lawsuit case evaluations are available through yourlegalhelp.com or by calling 1-800-399-0795.

Contact:
Wright & Schulte LLC
"An Experienced Defective Drug Law Firm"
1-800-399-0795
http://www.yourlegalhelp.com

Read the full story at http://www.prweb.com/releases/2013/12/prweb11391871.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Lipitor Lawsuits Continue to Mount, as Bernstein Liebhard LLP Notes Filing of New Claim Alleging an Association Between Lipitor and Diabetes
2. Dozens of Lipitor Lawsuits Involving Diabetes Allegations Moved to Federal Court, Bernstein Liebhard LLP Reports
3. Warning of Statin Drug Lipitor’s Risk of Type 2 Diabetes Came Too Late Say Patients Filing Lipitor Lawsuits
4. Lipitor Lawsuit News: Judicial Panel Denies Consolidation of Federal Cases, Rottenstein Law Group LLP Reports
5. Lipitor Lawsuit Website Launched by Bernstein Liebhard LLP to Provide Information to the Public Regarding Lipitor Side Effects, Ongoing Litigation
6. National Law Firm Baron and Budd Helping Women with Alleged Injuries from Lipitor Use Understand the Lipitor Lawsuit
7. National Law Firm Baron and Budd Responds to Disproportionate Harm Brought to Women Using Lipitor, According to Study
8. Lipitor News: Rottenstein Law Group LLP Comments on Boomers’ Favorite Drug
9. Lipitor Lawsuit News: Rottenstein Law Group LLP Responds to Reports of Lipitor Giveaway
10. Lipitor Lawsuit News: US Spending on Drugs Fell For First Time in 2012, Notes Rottenstein Law Group LLP
11. Lipitor Lawsuit News: Rottenstein Law Group Comments on FDA Approval of New Drug With Lipitor Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... The MIAMI Institute for Age Management and ... Adonis Maiquez MD, ABAARM. Dr. Adonis , Wellness Physician of the MIAMI Institute ... of the Institute for Functional Medicine. , He also heads up FITTLab, the comprehensive ...
(Date:5/26/2016)... ... May 26, 2016 , ... Power Systems, a ... first PowerWave Instructor Certification Course in Stoughton, Massachusetts. The course was led by ... through the 8 hour interactive course to qualify participants as certified PowerWave trainers. ...
(Date:5/26/2016)... ... May 26, 2016 , ... OncLive® ... added National Cancer Institute-designated University of Virginia (UVA) Cancer Center to ... OncLive’s editorial and marketing teams will publicize and promote public awareness of UVA ...
(Date:5/26/2016)... ... ... A health conscious snack that doesn't sacrifice taste? It's possible! In one ... buzz in the protein product community by offering an alternative to the traditional bar ... with 11 grams of protein and made from a healthy blend of high quality ...
(Date:5/26/2016)... ... May 26, 2016 , ... Workrite Ergonomics announced today ... to further develop their rapidly expanding portfolio of customer and end user accounts. ... in Marketing and an M.B.A. with concentration in management from Bryant University in ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... 2016  According to Kalorama Information, the world ... 2015.  Though these are challenging times in the ... success for companies that remain optimistic and seek ... growth prospects medical device companies spend a higher ... (R&D) than do companies in other industries.  Also, ...
(Date:5/25/2016)... PARIS , May 25, 2016 ... system disorders, announces that an oral presentation entitled "High doses ... the MS-SPI trial" will be given by Professor Ayman ... the 2nd Congress of the European Academy of Neurology (EAN) ... "MS and related disorders 3" will take place on Sunday, ...
(Date:5/24/2016)...   , ... primären Endpunkte und demonstriert Ebenbürtigkeit bei der Gesamtreinigung ... plus guter , Reinigung des ...      (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ) , ... von der MORA-Studie der Phase III für NER1006 ...
Breaking Medicine Technology: